{"id":195829,"date":"2024-09-07T09:23:58","date_gmt":"2024-09-07T14:23:58","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/09\/gene-therapy-restores-sight-with-up-to-10000-fold-vision-improvement"},"modified":"2024-09-07T09:23:58","modified_gmt":"2024-09-07T14:23:58","slug":"gene-therapy-restores-sight-with-up-to-10000-fold-vision-improvement","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/09\/gene-therapy-restores-sight-with-up-to-10000-fold-vision-improvement","title":{"rendered":"Gene therapy restores sight with up to 10,000-fold vision improvement"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/WsyQpaihUXU?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>This gene therapy treats LCA1, causing early childhood vision loss, affecting under 100,000 people:<\/p>\n<hr>\n<p>\u201cOne patient reported for the first time being able to navigate at midnight outdoors only with the light of a bonfire,\u201d said Cideciyan, who is also co-director of the Center for Hereditary Retinal Degenerations.<\/p>\n<p>The clinical trials were co-led by researchers from the Perelman School of Medicine at the University of Pennsylvania.<\/p>\n<p>The gene therapy (ATSN-101) is specifically designed to target and correct the genetic mutation in the GUCY2D gene. This <a href=\"https:\/\/interestingengineering.com\/health\/innovative-research-may-find-solutions-for-the-treatment-of-blindness\" rel=\"dofollow\">g<\/a><a href=\"https:\/\/interestingengineering.com\/health\/innovative-research-may-find-solutions-for-the-treatment-of-blindness\" target=\"_blank\" rel=\"dofollow\">e<\/a><a href=\"https:\/\/interestingengineering.com\/health\/innovative-research-may-find-solutions-for-the-treatment-of-blindness\" rel=\"dofollow\">ne<\/a> creates vision-imparting proteins. ATSN-101 is \u201cadapted from the AAV5 microorganism.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This gene therapy treats LCA1, causing early childhood vision loss, affecting under 100,000 people: \u201cOne patient reported for the first time being able to navigate at midnight outdoors only with the light of a bonfire,\u201d said Cideciyan, who is also co-director of the Center for Hereditary Retinal Degenerations. The clinical trials were co-led by researchers [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-195829","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/195829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=195829"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/195829\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=195829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=195829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=195829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}